Dynamic Technology Lab Private Ltd Acquires 4,845 Shares of Insulet Corporation $PODD

Dynamic Technology Lab Private Ltd boosted its holdings in Insulet Corporation (NASDAQ:PODD) by 221.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,034 shares of the medical instruments supplier’s stock after acquiring an additional 4,845 shares during the quarter. Insulet accounts for approximately 0.5% of Dynamic Technology Lab Private Ltd’s holdings, making the stock its 21st largest position. Dynamic Technology Lab Private Ltd’s holdings in Insulet were worth $1,999,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Nordea Investment Management AB lifted its holdings in shares of Insulet by 35.0% during the 4th quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after buying an additional 142,922 shares during the period. ING Groep NV lifted its holdings in shares of Insulet by 88.5% during the 3rd quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock valued at $5,341,000 after buying an additional 8,123 shares during the period. Jain Global LLC lifted its holdings in shares of Insulet by 148.2% during the 3rd quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock valued at $32,945,000 after buying an additional 63,719 shares during the period. Fisher Asset Management LLC lifted its holdings in shares of Insulet by 38.1% during the 3rd quarter. Fisher Asset Management LLC now owns 46,273 shares of the medical instruments supplier’s stock valued at $14,286,000 after buying an additional 12,754 shares during the period. Finally, Mitsubishi UFJ Trust & Banking Corp lifted its holdings in shares of Insulet by 26.5% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock valued at $12,484,000 after buying an additional 9,206 shares during the period.

Insider Transactions at Insulet

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.36% of the company’s stock.

Insulet Price Performance

Shares of Insulet stock opened at $149.70 on Friday. Insulet Corporation has a one year low of $140.63 and a one year high of $354.88. The stock’s fifty day moving average is $169.92 and its 200 day moving average is $232.67. The stock has a market cap of $10.37 billion, a P/E ratio of 34.81, a P/E/G ratio of 1.17 and a beta of 1.13. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same period last year, the firm earned $1.02 EPS. Insulet’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts anticipate that Insulet Corporation will post 6.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PODD has been the topic of several research analyst reports. Jefferies Financial Group lowered their price target on Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. UBS Group set a $219.00 price target on Insulet in a report on Thursday. Wall Street Zen raised Insulet from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Sanford C. Bernstein decreased their target price on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Bank of America decreased their target price on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Twenty-one analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $240.78.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.